BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31162796)

  • 1. Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor.
    Thysell E; Vidman L; Ylitalo EB; Jernberg E; Crnalic S; Iglesias-Gato D; Flores-Morales A; Stattin P; Egevad L; Widmark A; Rydén P; Bergh A; Wikström P
    Mol Oncol; 2019 Aug; 13(8):1763-1777. PubMed ID: 31162796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer.
    Ylitalo EB; Thysell E; Landfors M; Brattsand M; Jernberg E; Crnalic S; Widmark A; Hultdin M; Bergh A; Degerman S; Wikström P
    Clin Epigenetics; 2021 Jun; 13(1):133. PubMed ID: 34193246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
    Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C.
    Thysell E; Köhn L; Semenas J; Järemo H; Freyhult E; Lundholm M; Thellenberg Karlsson C; Damber JE; Widmark A; Crnalic S; Josefsson A; Welén K; Nilsson RJA; Bergh A; Wikström P
    Mol Oncol; 2022 Feb; 16(4):846-859. PubMed ID: 34889043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
    Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
    Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients.
    Crnalic S; Hörnberg E; Wikström P; Lerner UH; Tieva A; Svensson O; Widmark A; Bergh A
    Endocr Relat Cancer; 2010 Dec; 17(4):885-95. PubMed ID: 20688881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki67 and prostate specific antigen are prognostic in metastatic hormone naïve prostate cancer.
    Spyratou V; Freyhult E; Bergh A; Thellenberg-Karlsson C; Wikström P; Welén K; Josefsson A
    Acta Oncol; 2023 Dec; 62(12):1698-1706. PubMed ID: 37713321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome.
    Hammarsten P; Josefsson A; Thysell E; Lundholm M; Hägglöf C; Iglesias-Gato D; Flores-Morales A; Stattin P; Egevad L; Granfors T; Wikström P; Bergh A
    Mod Pathol; 2019 Sep; 32(9):1310-1319. PubMed ID: 30980038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial and Stromal Characteristics of Primary Tumors Predict the Bone Metastatic Subtype of Prostate Cancer and Patient Survival after Androgen-Deprivation Therapy.
    Wikström P; Bergström SH; Josefsson A; Semenas J; Nordstrand A; Thysell E; Crnalic S; Widmark A; Karlsson CT; Bergh A
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential.
    Miller ET; You S; Cadaneanu RM; Kim M; Yoon J; Liu ST; Li X; Kwan L; Hodge J; Quist MJ; Grasso CS; Lewis MS; Knudsen BS; Freeman MR; Garraway IP
    BMC Cancer; 2020 May; 20(1):398. PubMed ID: 32380981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.
    Zhao SG; Chang SL; Erho N; Yu M; Lehrer J; Alshalalfa M; Speers C; Cooperberg MR; Kim W; Ryan CJ; Den RB; Freedland SJ; Posadas E; Sandler H; Klein EA; Black P; Seiler R; Tomlins SA; Chinnaiyan AM; Jenkins RB; Davicioni E; Ross AE; Schaeffer EM; Nguyen PL; Carroll PR; Karnes RJ; Spratt DE; Feng FY
    JAMA Oncol; 2017 Dec; 3(12):1663-1672. PubMed ID: 28494073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival and PSA-markers for mortality and metastasis in nonmetastatic prostate cancer treated with androgen deprivation therapy.
    Nguyen-Nielsen M; Liede A; Maegbaek ML; Borre M; Harving N; Hernandez RK; Sørensen HT; Ehrenstein V
    Cancer Epidemiol; 2015 Aug; 39(4):623-32. PubMed ID: 26100365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic signatures associated with high infiltration of Tregs in bone metastatic prostate cancer.
    Meng F; Han X; Min Z; He X; Zhu S
    Aging (Albany NY); 2021 Jul; 13(13):17442-17461. PubMed ID: 34229299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
    Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
    JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolomic profiles of intact tissues reflect clinically relevant prostate cancer subtypes.
    Dudka I; Lundquist K; Wikström P; Bergh A; Gröbner G
    J Transl Med; 2023 Nov; 21(1):860. PubMed ID: 38012666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.
    Weiner AB; Liu Y; Hakansson A; Zhao X; Proudfoot JA; Ho J; Zhang JH; Li EV; Karnes RJ; Den RB; Kishan AU; Reiter RE; Hamid AA; Ross AE; Tran PT; Davicioni E; Spratt DE; Attard G; Lotan TL; Lee Kiang Chua M; Sweeney CJ; Schaeffer EM
    Cancer; 2023 Jul; 129(14):2169-2178. PubMed ID: 37060201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications.
    Iglesias-Gato D; Thysell E; Tyanova S; Crnalic S; Santos A; Lima TS; Geiger T; Cox J; Widmark A; Bergh A; Mann M; Flores-Morales A; Wikström P
    Clin Cancer Res; 2018 Nov; 24(21):5433-5444. PubMed ID: 30042207
    [No Abstract]   [Full Text] [Related]  

  • 19. A Novel Radiographic Pattern Related to Poor Prognosis in Patients with Prostate Cancer with Metastatic Spinal Cord Compression.
    Wänman J; Abul-Kasim K; Semenas J; Thysell E; Bergh A; Wikström P; Crnalic S
    Eur Urol Open Sci; 2023 Feb; 48():44-53. PubMed ID: 36743403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
    Smith MR; Kabbinavar F; Saad F; Hussain A; Gittelman MC; Bilhartz DL; Wynne C; Murray R; Zinner NR; Schulman C; Linnartz R; Zheng M; Goessl C; Hei YJ; Small EJ; Cook R; Higano CS
    J Clin Oncol; 2005 May; 23(13):2918-25. PubMed ID: 15860850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.